accentureReinventingR&Din the age of AlHow inteligent technologies are transformingthe Biopharma Industry
ContentsPaqa3PageGPage12Page30PrefaceAbout the research'TheR&DopportunityReinventingtheR&DConclusionorganizationContents|Preface|RdinventingtheR&Darganization|Conclusior
PrefaceR&D leaders across theindustry are unanimous about the challenges ahead, voicing concerns likenowhavetochoasebetweInowhave totakebiggerrisls to scaleInowhaveto considermyriedstmontsthatinvestinginanasset(acolinicaltridlorwillcmatevolueinashortteaxtemalinovationlvs.anemergingent and manufacturingsothat Ican fundessealtechnologyteahndlogyand cmpability investments thet wilbechdioes aroundmedalitybeforeanaritikaltoR&DreinventionandpayeoffLie-changing interventions that ha ve previously benpipeohreant; are now within rsach far the biopharma indastry, mad posible troughan incmasigl sophisticated understanding ofumanbiology couplesd withunparalleled advanoces intechnology.On the atherhandl, the industrys research and developrment(R&D) produrctivity has remainedlargaly unchanged foraCreating therapies from ba ie acience and mal ing te be a ue af adivaneces intechnolagy reaiuies acrmpariestoreinvent their R&D argarization. Bopharme companiesthat embraotechnolog,rinventfhlirworkiroesanderfoausthei arganizaionaliriaies wllimpnaveR&.Defienoyandpatientautcosecure growthin an increasinglychallenging macro enviranment.GontentsI
AuthorsAcknowledaementsTomLehmannThe authors would like to thank the foallowing peapleagingDiacto,OlobalLeadRADfartheiraontributicrsAecertuNeLiNeSeiancllBarry Heaveyfor his expertise on developling andAkash Trived for his expertise onoptimizing clinical trials.SelanKaraca-GriffinAlexBlumbargJoanna Lisiocka forhersuppart antheAl-mediateddrugdershipPiinricalResdiscovery companyanalysesNaohCromandAnandia Rowniathesupprtlanthe devebpmontd thesR&Desecauive sarvoey.gathering Ac centure Subject Mater Expert input.Contents|Preface
typadenpuovstupoursAboutthe researchOur researchmethadology was threefold.1.Wesurveyed75R&Doaortinsfomtheiop20 bopharma companils ty anulrevenue toing tointegrateaundersand th aurmntandeapeandthe decionofa R&D, while intelligent technalogiessuchchange2. We conducted in cdepth interviews with industrysaubiectmatterexpertsand usedour internalexperise3. We developed austom analyses, indluding a modal toantify the uolit in future cotential andanindex tocoess(PTRS)ratesTo achieve that uplift, careful consideration of futurepotential a nd value of the assets must be done atearlierstages than traditional value discusionsContents|Preface
The R&Dopportunity
Al biopharma CEOs agree that R& D presents the most significant oppor tunity within the biopharma valuechain when it comes to creating value with intelligent technologies.willikelybe atrisk bythe endof the decade,matobringin the U.S, and lossafartificial intelligened throughantibadydrug con(ADCs)and racdiolligpand the rapy have bexowever,the industry 's A& D praductivity hasgtechnolagy fore the complexitesdf biapharma'samethetoppriaritycompetitivemarkethavecontinue...
